IV glutathione: the FDA is investigating, and dermatology already ruled
On August 27, 2026 the FDA said it was aware of at least 30 patients who reacted badly to intravenous glutathione — fever, chills, signs of shock, some hospitalized — all of it traced to one lot of glutathione that was labeled as dietary supplement grade and used to make injections anyway. Two Texas pharmacies had already recalled product for excess endotoxin.
What this comes down to
- The FDA is actively investigating adverse events from compounded IV glutathione and named the supplier and lot number in its alert.
- The material was dietary supplement grade. That grade is not made for injection, and impurities including endotoxins are the predictable result.
- A 2025 systematic review in the International Journal of Dermatology found one placebo-controlled study of the intravenous route and concludes IV glutathione is contraindicated.
- Oral and topical glutathione have a real, if modest, evidence base for skin lightening. The injectable route is the one under fire.
What the FDA published
The agency's compounding risk alert names Medisca Inc. of Plattsburgh, New York as the supplier and lot #229536 as the material, distributed to multiple compounding pharmacies[1]. Medisca told the FDA on August 20, 2026 that it had warned its US customers not to use the dietary supplement grade material in injectables. Reported reactions included fever, chills, pain, dizziness, signs of shock and sepsis-like symptoms, consistent with excessive endotoxin exposure.
“Compounders are responsible for ensuring all components used in injectable drugs are appropriate for their intended use and should not use dietary supplement grade ingredients when making injectable drugs.”
[1]
The alert also notes that the FDA raised the same concern in 2019 and remains worried. That is the part worth sitting with: this is a repeat, not a first — and it is the most recent entry on the agency's running list of compounding risk alerts[4]. Glutathione itself is not an approved injectable therapy; the only place it appears in Drugs@FDA is as a component of an irrigating solution used in eye surgery[3].
Does injected glutathione do anything?
For skin lightening, which is what most of it is sold for, a 2025 systematic review in the International Journal of Dermatology went through the literature and found exactly one placebo-controlled study of the intravenous route[2]. Topical glutathione at 0.5% beat both 0.1% and placebo. Five randomized trials of oral glutathione at 250 to 500 mg a day showed a significant reduction in melanin index against placebo. The review's conclusion on the injectable route is unambiguous.
“IV glutathione is contraindicated due to lack of efficacy and side effects.”
[2]
Glutathione infusions are also sold for detoxification, immune support and liver health. Those claims have a different problem: there are 110 randomized trials involving intravenous or infused glutathione in PubMed, and they are overwhelmingly in specific clinical settings — cardiac procedures, chemotherapy toxicity, critical care — not in healthy adults buying a drip.
PubMed, via the E-utilities API
glutathione[tiab] AND (intravenous[tiab] OR infusion[tiab]) AND "randomized controlled trial"[pt] AND "humans"[mh]
Returned 110. Positive control — magnesium, identical filter — returned 645 through the identical filter in the same session.
A fabricated drug name run through the identical filter in the same session returned 0. A count is not an endorsement — this one is included because it is large, and a large trial count in unrelated clinical settings is exactly the number a marketing page borrows without saying what was studied.
What this changes about buying one
The question to ask a clinic or telehealth company stopped being philosophical in August 2026. Ask which pharmacy compounds their glutathione, whether that pharmacy sourced material from the named lot, and whether the ingredient was pharmaceutical grade or supplement grade. A company that can't answer the third question is telling you something.
The same due diligence applies to every compounded injectable on these menus, GLP-1s included — the FDA's list of telehealth red flags is short and specific, and we walk through it in how telehealth prescribing actually works. For what we check about a seller before we grade it, see how we grade.
Questions people actually ask
Is IV glutathione safe?
The FDA is investigating reports of at least 30 patients who had reactions to compounded IV glutathione in 2026, including hospitalizations, traced to supplement-grade material used in injections. The risk in those cases came from what the product was made of, not from glutathione as a molecule.
Does IV glutathione lighten skin?
A 2025 systematic review found one placebo-controlled study of the intravenous route and concluded that IV glutathione is contraindicated for lack of efficacy and side effects. Oral and topical forms did show measurable effects in that same review.
Is glutathione an FDA-approved drug?
Not as an injectable therapy. Glutathione appears in Drugs@FDA only as a component of an intraocular irrigating solution used in eye surgery, which is a different product for a different purpose.
What is dietary supplement grade, and why does it matter?
It is material manufactured to the standards for something you swallow, where the gut handles impurities that would be dangerous injected. Endotoxin is the specific problem: harmless enough by mouth, capable of causing fever, shock and death in a vein.
Sources
Every source here was fetched and read for this article, with the identifier taken off the record that came back and the claim it supports written down beside it. All of it was read in September 2026, the same session the rest of this page draws on.
- FDA reminds compounders not to use dietary supplement grade glutathione for injectables. U.S. Food and Drug Administration, 2026. Source · Document dated August 2026The FDA is aware of at least 30 patients who experienced adverse events after intravenous glutathione compounded from Medisca lot #229536, labeled dietary supplement grade; two Texas pharmacies recalled product for elevated endotoxin; Medisca notified the agency on August 20, 2026 that it had warned US customers.
- Glutathione as a skin-lightening agent and in melasma: a systematic review. International Journal of Dermatology, 2025. PMID 39444151 · doi:10.1111/ijd.17535 · Topical 0.5% glutathione outperformed 0.1% and placebo; five randomized trials of oral glutathione at 250 to 500 mg daily reduced melanin index against placebo; only one placebo-controlled study of intravenous glutathione was found, and the review concludes that IV glutathione is contraindicated for lack of efficacy and side effects.
- Drugs@FDA: FDA-Approved Drugs, queried through the openFDA API. U.S. Food and Drug Administration, 2026. Source · Glutathione appears in Drugs@FDA as a component of an intraocular irrigating solution, not as an approved injectable therapy.
- Compounding Risk Alerts. U.S. Food and Drug Administration, 2026. Source · Document dated August 2026The glutathione alert is the most recent entry on the FDA's compounding risk alert list, dated August 27, 2026.